FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Jones James B  (Last) (First) (Middle)  C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300  (Street)  PARSIPPANY NJ 07054					3. Dat 01/12	Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [ PCRX ]      Date of Earliest Transaction (Month/Day/Year) 01/12/2016  4. If Amendment, Date of Original Filed (Month/Day/Year)									X Individue)	Il appli Directo Officer below SVP	icable) or r (give title ) & Chief N  Joint/Group filled by One		Owner or (specify w) cer c Applicable
(City)	(S	rate) (Z	Zip)																
		Tabl	e I - N	lon-Deriv	ative S	Secu	ıritie	s Acc	uired, [	Disp	osed o	f, or	Bene	ficia	lly O	wne	d		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day						Execution Date,			3.						3, 4 Secui Bene Owne		ially	6. Ownership Form: Direct (D) or Indirect (I)	of Indirect Beneficial Ownership
									Code	v	Amount (A)		(A) or (D)	Price	,   F	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	(Instr. 4)
Common Stock 01/12/20					.016			P		1,000	)	A	\$66		1,000		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rative   Conversion   Date   Execution Date, rity   or Exercise   (Month/Day/Year)   if any		Code (Ir	ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Expiration Date (Month/Day/Year)  Date Expiration			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)  Amount or Numbrof Title Shares		ount nber	8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4)	Beneficial Ownership		

Explanation of Responses:

Remarks:

/s/ Kristen Williams, Attorneyin-Fact 01/14/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).